Teladoc Stock Plummets After Revenue Miss and Slashed Full-Year Guidance

Teladoc Health (TDOC) shares plunged nearly 20% in pre-market trading on Thursday after the company reported second-quarter revenue that missed analyst expectations and sharply lowered its financial outlook for the rest of the year.

Earnings and Guidance Disappoint

For the second quarter of 2026, Teladoc posted revenue of $606.9 million, a 4% decline from the prior year and below the analyst consensus of approximately $615 million, according to a report from Investing.com. While its adjusted loss per share of $0.21 was narrower than the expected $0.25 loss, the bottom-line beat was overshadowed by the top-line miss and a grim forecast.

The company significantly reduced its guidance for the upcoming quarter and the full year. Management now expects third-quarter revenue between $569 million and $609 million, well short of the $629 million Wall Street had anticipated. Full-year 2026 revenue guidance was cut by about 5% to a range of $2.36 billion to $2.45 billion, down from a prior forecast of $2.48 billion to $2.58 billion.

BetterHelp Weakness Drives Shortfall

The primary driver for the disappointing results was the company's direct-to-consumer mental health segment, BetterHelp. Revenue for the unit declined 12% year-over-year to $212.6 million, which the company attributed to an accelerating exit of cash-paying users in late May and June.

Ad

CEO Chuck Divita also noted that while demand for insurance-covered services remains strong, the company is facing provider capacity constraints. These limitations are hindering its ability to convert that demand into immediate revenue, adding another layer of operational pressure.

Market Reaction

Investors reacted swiftly to the news, sending Teladoc shares down 19.8% to $7.36 in pre-open trading, approaching the low end of its 52-week range of $4.40–$9.89. The sharp sell-off reflects deep concerns over the company's near-term growth trajectory, particularly within its consumer-facing business.

The negative report landed in a broadly cautious market, with a risk-off tone prevailing after the Federal Reserve's latest interest rate decision and a surge in long-term Treasury yields, compounding the pressure on the stock.